Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2016

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions

Kaposi Sarcoma

Interventions

DRUG

liposomal doxorubicin

liposomal doxorubicin IV day 1 of a 28-day cycle

DRUG

pomalidomide

pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH